The role of HLA-DQ heterodimers in HLA-matched unrelated-donor transplantation
| Feature* . | Population . | Clinical endpoint . | Genotype . | Patients, n . | Hazard ratio (95% CI; P value)† . |
|---|---|---|---|---|---|
| HLA-DQ group genotype | HLA-matched patients | Relapse | G1G1 | 1597 | 1.0 |
| G1G2 | 2434 | 1.20 (1.08-1.34; .0009) | |||
| G2G2 | 848 | 1.22 (1.06-1.40; .006) | |||
| Disease-free survival | G1G1 | 1688 | 1.0 | ||
| G1G2 | 2566 | 1.08 (1.01-1.17; .03) | |||
| G2G2 | 897 | 1.11 (1.00-1.22; .04) | |||
| Dose effect of number of G1 molecules | HLA-matched patients | Relapse | No G1 | 848 | 1.0 |
| One G1 | 2702 | 0.97 (0.85-1.10; .65) | |||
| Two G1 | 495 | 0.82 (0.68-0.99; .04) | |||
| Four G1 | 834 | 0.85 (0.72-1.00; .05) | |||
| Disease-free survival | No G1 | 897 | 1.0 | ||
| One G1 | 2858 | 0.96 (0.88-1.05; .38) | |||
| Two G1 | 519 | 0.89 (0.78-1.01; .07) | |||
| Four G1 | 877 | 0.93 (0.83-1.04; .20) | |||
| Dose effect of number of G2 molecules | HLA-matched patients | Relapse | No G2 | 1597 | 1.0 |
| One G2 | 2661 | 1.19 (1.07-1.33; .001) | |||
| Two G2 | 107 | 1.53 (1.13-2.08; .006) | |||
| Four G2 | 514 | 1.25 (1.06-1.48; .008) | |||
| Disease-free survival | No G2 | 1688 | 1.0 | ||
| One G2 | 2806 | 1.07 (1.00-1.15; .06) | |||
| Two G2 | 115 | 1.24 (0.99-1.54; .06) | |||
| Four G2 | 542 | 1.12 (1.00-1.26; .05) |
| Feature* . | Population . | Clinical endpoint . | Genotype . | Patients, n . | Hazard ratio (95% CI; P value)† . |
|---|---|---|---|---|---|
| HLA-DQ group genotype | HLA-matched patients | Relapse | G1G1 | 1597 | 1.0 |
| G1G2 | 2434 | 1.20 (1.08-1.34; .0009) | |||
| G2G2 | 848 | 1.22 (1.06-1.40; .006) | |||
| Disease-free survival | G1G1 | 1688 | 1.0 | ||
| G1G2 | 2566 | 1.08 (1.01-1.17; .03) | |||
| G2G2 | 897 | 1.11 (1.00-1.22; .04) | |||
| Dose effect of number of G1 molecules | HLA-matched patients | Relapse | No G1 | 848 | 1.0 |
| One G1 | 2702 | 0.97 (0.85-1.10; .65) | |||
| Two G1 | 495 | 0.82 (0.68-0.99; .04) | |||
| Four G1 | 834 | 0.85 (0.72-1.00; .05) | |||
| Disease-free survival | No G1 | 897 | 1.0 | ||
| One G1 | 2858 | 0.96 (0.88-1.05; .38) | |||
| Two G1 | 519 | 0.89 (0.78-1.01; .07) | |||
| Four G1 | 877 | 0.93 (0.83-1.04; .20) | |||
| Dose effect of number of G2 molecules | HLA-matched patients | Relapse | No G2 | 1597 | 1.0 |
| One G2 | 2661 | 1.19 (1.07-1.33; .001) | |||
| Two G2 | 107 | 1.53 (1.13-2.08; .006) | |||
| Four G2 | 514 | 1.25 (1.06-1.48; .008) | |||
| Disease-free survival | No G2 | 1688 | 1.0 | ||
| One G2 | 2806 | 1.07 (1.00-1.15; .06) | |||
| Two G2 | 115 | 1.24 (0.99-1.54; .06) | |||
| Four G2 | 542 | 1.12 (1.00-1.26; .05) |
n = 5164.
The most frequently observed G2 molecule in patients bearing G1G2 and G2G2 was DQA1*01:02P-DQB1*06:02P (0.38 haplotype frequency); those with G1G1 most frequently encoded DQA1*05:01P-DQB1*02:01P (28.8%).
Models adjusted for preparative regimen, diagnosis, cytomegalovirus serostatus, patient age, donor age, stem cell source, patient sex, donor sex, use of total body irradiation, use of T-cell depletion, presence of DPB1 mismatch, and year of transplantation (genotype model).